Rapamycin Selectively Inhibits the Growth of Childhood Rhabdomyosarcoma Cells through Inhibition of Signaling via the Type I Insulin-like Growth Factor Receptor

Michael B. Dilling, Peter Dias, David N. Shapiro, Glen S. Germain, Randall K. Johnson, Peter J. Houghton

Research output: Contribution to journalArticle

129 Scopus citations


We show that cell lines derived from childhood alveolar rhabdomyosarcoma (RMS) are very sensitive to the growth-inhibitory effects of the immunosuppressive agent rapamycin (RAP), compared to other human cell lines (50% inhibitory concentration range of 0.1-8 ng/ml, compared to 1280 to >10,000 ng/ml). Our data suggest that the sensitivity of RMS lines is due to RAP inhibition of insulin-like growth factor 1 receptor-mediated signaling, which is essential for continued proliferation of RMS cells. The embryonal RMS line Rhl, which was resistant to RAP in serum-containing medium (50% inhibitory concentration, 4180 ng/ml), was highly sensitive under autocrine conditions of growth, indicating that resistance was due to paracrine signaling pathways insensitive to RAP action. FK506 reversed RAP action in all cell lines, indicating a dependence on completing with the cytosolic FK506-binding protein for activity.

Original languageEnglish (US)
Pages (from-to)903-907
Number of pages5
JournalCancer Research
Issue number4
Publication statusPublished - Feb 1994


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this